Results 41 to 50 of about 756,250 (282)

Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study

Kidney Medicine
Rationale & Objective: Optimal antihypertensive therapy with renoprotective effects is essential to slow diabetic kidney disease progression. We evaluated the impact of dihydropyridine calcium channel blockers on kidney outcomes in patients with type
Timna Agur, Tali Steinmetz, Shira Goldman, Boris Zingerman, Dana Bielopolski, Eviatar Nesher, Ittai Fattal, Eshcar Meisel, Benaya Rozen-Zvi   +8 more
doaj   +1 more source

The human renin infused rat: use as an in vivo model for the biological evaluation of human renin inhibitors

, 1999
The human renin infused rat model (HRIRM) was used as an in vivo small-animal model for evaluating the efficacy of a collection of inhibitors of human renin. The intravenous infusion of recombinant human renin (2.4 µg·kg-1·min-1) in the ganglion-blocked,
Francine Liard, Paul Anderson, Jorge Jaramillo, Gordon Bolger, Daniel Lamarre, Bruno Simoneau, Jean-Claude Vigeant, Grace Jung, Diane Thibeault, Louise Pilote   +9 more
core   +1 more source

Chinese Expert Consensus on the Clinical Application of Finerenone in Geriatric Comorbidities

AGING MEDICINE, EarlyView.
Mineralocorticoid receptor (MR) overactivation drives inflammation, oxidative stress, and fibrosis in the heart, kidneys, and vasculature, leading to cardiorenal dysfunction. MR signaling promotes hypertrophy, remodeling, and injury through pathways like oxidative stress and inflammation, resulting in vascular stiffness and progressive organ damage ...
Xiaoming Wang, Cuntai Zhang
wiley   +1 more source

Present and Future in the Treatment of Diabetic Kidney Disease

Journal of Diabetes Research, 2015
Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression.
Borja Quiroga, David Arroyo, Gabriel de Arriba   +2 more
doaj   +1 more source

P4.18 ANTIHYPERTENSIVE ACTIVITY OF LONG CHAIN FATTY ACID DERIVATIVES OF FLAVONOIDS VIA INHIBITION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS)

Artery Research, 2013
Hypertension is a contributing factor to pathophysiology of vascular damage and accelerated arterial stiffening. Renin-angiotensin-aldosterone system (RAAS) inhibitors are widely used for treatment of persistent hypertension.
Bhullar Khushwant Singh, Zia ullah, Rupasinghe Vasantha   +2 more
doaj   +1 more source

Targetable NOTCH1 rearrangements in reninoma

Nature Communications, 2023
Reninomas are exceedingly rare renin-secreting kidney tumours that derive from juxtaglomerular cells, specialised smooth muscle cells that reside at the vascular inlet of glomeruli.
Taryn D. Treger, John E. G. Lawrence, Nathaniel D. Anderson, Tim H. H. Coorens, Aleksandra Letunovska, Emilie Abby, Henry Lee-Six, Thomas R. W. Oliver, Reem Al-Saadi, Kjell Tullus, Guillaume Morcrette, J. Ciaran Hutchinson, Dyanne Rampling, Neil Sebire, Kathy Pritchard-Jones, Matthew D. Young, Thomas J. Mitchell, Philip H. Jones, Maxine Tran, Sam Behjati, Tanzina Chowdhury   +20 more
doaj   +1 more source

Role of cGMP as second messenger of adenosine in the inhibition of renin release [PDF]

, 1988
Adenosine is known to be a potent inhibitor of renin release from the kidneys. The aim of this study was to investigate the transmembrane signalling avenue that the second messenger of adenosine causes inhibition of renal renin release.
Kurtz, Armin, Della Bruna, R., Bauer, Christian, Pfeilschifter, J., Bauer C, Kurtz A, Della Bruna R, Pfeilschifter J   +7 more
core   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Renin as a target of direct pharmacological block in arterial hypertension

Терапевтический архив, 2009
Renin is a basic component of renin-angiotensin-aldosteron system which contributes much to the activity of this system. Renin and its precursor prorenin can interact with prorenin receptors thus inducing hypertrophy and fibrogenesis in target tissues ...
Nikolay Alekseevich Mukhin, V V Fomin, N A Mukhin, V V Fomin   +3 more
doaj